Abstract: An ovel cleavable amphiphilic peptide (CAP)w as designed to be specifically responsive to fibroblast activation protein-a (FAP-a), ap rotease specifically expressed on the surface of cancer-associated fibroblasts.T he CAP self-assembled into fiber-like nanostructures in solution, while the presence of hydrophobic chemotherapeutic drugs readily transformed the assemblies into drug-loaded spherical nanoparticles.T he disassembly of these nanoparticles (CAP-NPs) upon FAP-a cleavage resulted in rapid and efficient release of the encapsulated drugs specifically at tumor sites.T his Transformers-like drug delivery strategy could allowthem to disrupt the stromal barrier and enhance local drug accumulation. Therapeutic results suggested that drug-loaded CAP-NPs hold promising tumor specificity and therapeutic efficacy for various solid tumor models,c onfirming its potential utility and versatility in antitumor therapy.
Nanomaterial-based drug delivery systems have long been seen as particularly promising for cancer therapy because of their great potential for improving drug specificity,b iocompatibility,pharmacokinetic features,and antitumor efficacy. [1] However,f or most particulate-based drug carriers,t he heterogeneity among tumor cells and the presence of complex stromal cell barriers are still great challenges limiting their tumor-targeting and -penetrating performances, [2, 3] and strategies to overcome tumor heterogeneity and to break stromal barriers are urgently needed. [2, 4] Cancer-associated fibroblasts (CAFs), the predominant cell type in the tumor stroma, [5] form am ajor barrier that impedes penetration of nanoparticulate therapeutics and even molecular drugs into solid tumors. [6] Compared to tumor cells that show diverse marker proteins among different tumor types,C AFs selectively overexpressed certain proteins,s uch as a-smooth muscle actin (a-SMA) and fibroblast-activated protein-a (FAP-a), in almost all solid tumors but not normal tissues. [5, 7, 8] Consequently,d evelopment of smart nanomaterials responding to CAFs may be aspecific and efficient strategy to overcome the aforementioned obstacles,l eading to increased drug perfusion and improved antitumor efficacy.
Peptides and peptide derivatives,o wing to their biocompatibility,c hemical versatility,a nd biological recognition abilities,h ave been widely utilized as building blocks to construct soft functional biomaterials for specific applications,s uch as tissue engineering and drug delivery. [9] Extensive studies have demonstrated that tailor-made peptides can self-assemble into unique secondary structures or nanostructures. [10] Moreover,certain peptides derived from degradation or cleavage of antibodies or collagens exhibit specific targeting capacity and enzymatic activity. [11] These features render peptides extremely useful in the construction of versatile, multi-functional, and stimuli-responsive nanostructures for drug delivery and release, [12] especially in tumor tissues overexpressing proteases.
Herein we report an ovel CAF-targeting drug delivery nanosystem based on acleavable amphiphilic peptide (CAP) designed to be specifically responsive to FAP-a,amembranebound serine protease specifically expressed on CAFs. [13] In aqueous solution, CAPmonomers readily self-assembled into nanofibers because of their amphiphilicity,w hich would transform into spherical nanoparticles (NPs) upon encapsulation of hydrophobic drugs.W hene ntered into tumor stroma, the CAPm olecules were cleaved by FAP-a,l osing amphiphilicity and causing the NPs to rapidly disassemble, thereby discharging their cargoes.T his stimulus-responsive nanocarrier is potentially applicable for the delivery of ab road spectrum of poorly soluble chemotherapeutic drugs, being able to greatly enhance tumor targeting and drug delivery efficacy. As FAP-a is specifically expressed and activated on CAFs in over 90 %o fh uman carcinomas, [8] aF AP-a-targeting drug delivery system can be particularly desirable in establishing an efficient treatment of ab road range of cancers.
TheC AP monomer had as equence of Ac-Ala-ThrLys(C18)-Asp-Ala-Thr-Gly-Pro-Ala-Lys(C18)-Thr-Ala-NH 2 and displayed aG emini-like structure (Figure 1a) . [14] Its hydrophilic domain contains the amino acid residue sequence Gly-Pro-Ala-X that can be specifically cleaved by FAP-a. added into the hydrophilic domain to increase its hydrophilicity,and an aspartic acid (Asp) containing carboxyl group was incorporated to provide negative charges for the hydrophilic head at pH 7.4, to decrease nonspecific phagocytosis by the reticuloendothelial system (RES) and prolong blood circulation time in vivo. [16, 17] TheN -terminus was protected with acetyl (Ac) to avoid undesirable cleavage by the lymphatic vessel-expressed protease,dipeptidyl peptidase IV (DPPIV), which shares the same substrates with FAP-a but is unable to cleave N-terminus blocked peptides.
[18] Furthermore,t wo octadecanoic acid chains were linked to the sidechains of the lysine residues of CAPtoform the hydrophobic domain. We also synthesized an un-cleavable amphiphilic peptide (UAP) (Supporting Information, Figure S1a )w ith as imilar structure and sequence of CAPa sac ontrol. The purity of CAP and UAPwas over 95 % (Figure S1 b, S1 c). The responsiveness of CAPand UAPtowards FAP-a and DPPIV was detected by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) (Figure S2 ). After incubation with FAP-a for 3h,t he peak of CAP( M = 1705) disappeared with the emergence of two fragment peaks (M1 = 655, M2 = 1068), which correspond to the two predicted digested segments:Ac-Ala-Lys(C18)-AspAla-Thr-Gly-Pro-OH and Ala-Lys(C18)-Thr-Ala-NH 2 .When CAPw as incubated with DPPIV,t he peak M = 1705 remained and no other peaks emerged, indicating that CAP cannot be cleaved by the non-tumor related enzyme DPPIV. As expected, UAPe xhibited no responsiveness towards either FAP-a or DPPIV.B oth CAP and UAPh ave low critical micelle concentration (CMC) (CAP,0 .66 mm ;U AP, 0.89 mm)i nP BS buffer ( Figure S3 ), implying that they are able to self-assemble into core-shell structures at concentrations equal to or above the CMC.
Thed rug loading capacity of CAPw as first studied with the hydrophobic drug doxorubicin (Dox). Dox and CAP were dissolved in dimethyl sulfoxide and then diluted in water. After being ultrasonicated for 3min and further incubated for 1h,t he product exhibited am ixture of multi-shaped nanostructures,including nanofibers,spherical NPs and mace-like structures,a sd emonstrated by transmission electron microscopy (TEM) measurements (Figure 1b,I ). However, the assembled product transformed into uniform NPs after prolonged ultrasonication (Figure 1b,II) . Thus,w eh ypothesize that the encapsulation of drugs by amphiphilic peptides may involve three processes ( Figure 1c ): peptide self-assembly into fiber-like structures,co-assembly of hydrophobic Dox and peptides into spherical NPs,and Dox-induced reassembly of nanofiber into NPs.
Further investigation was then carried out on the selfassembly behavior of engineered amphiphilic peptides. According to Israelachvilis surfactant number theory, [19, 20] both the CAPa nd UAPm onomers have ad imensionless packing parameter P (P = v/al;w here v = volume of hydrophobic tail, a = area of hydrophilic head group,a nd l = monomer length) between 0.5 and 1b ecause of their short hydrophilic domains yet long hydrophobic tails (CAP, P = 0.58;U AP, P = 0.56), which predicts atendency to form fibershaped micelles during self-assembly.T his was confirmed by TEM analysis that showed that in the absence of Dox, CAP dynamically self-assembled into well-ordered, thin nanofibers to gradually shrink, which leads to the transformation of the aggregates to long and thin fiber-like structures with water completely expelled from the hydrophobic core (transient state II). Finally,t he resulting nanofibers were dispersed, capable of forming stable structures owing to their negatively charged surfaces,p rovided by the Asp carboxyl group side chains.T he UAPh ad as imilar self-assembly process with CAP( Figure S4 b) . Theh eight of these nanofibers,a s measured by atomic force microscope (AFM), was approximately 4nm ( Figure S5 ), confirming the formation of nanofibers by am onolayer of CAPm olecules.
However,w hen Dox was added into the system, the assembled product changed from nanofibers to nanospheres. It is easy to imagine that amphiphilic peptide monomers could directly encapsulate the drug through ao ne-step coassembly process,w here hydrophobic drug molecules form the hydrophobic cores that induce the alkyl chains of peptide to assemble around them (Figure 1c) . Nonetheless,since selfassembly of peptide and co-assembly of peptide and drug simultaneously occurred during drug loading, areassembly of the self-assembled peptide nanofibers upon interaction with the drug was probably involved. To exploit the reassembly process,d iverse small molecular weight hydrophobic drugs were incubated with CAPi na queous solution under ultrasonication for different time intervals and the morphologies of the assembled products were observed. After co-incubation of CAPw ith Dox for 1min, silkworm cocoon-like structures emerged among nanofibers (Figure 2b ). When the ultrasonication time was increased to 3min, the amount of nanofibers significantly decreased and many spherical particles appeared. After 5min or longer ultrasonication time, nanofibers disappeared and were ultimately transformed to spherical NPs.T he morphology of the NPs was unchanged even after incubation with serum for 48 h( Figure S6 ), indicating their high stability under physiological conditions. Substituting Dox with two other first-line chemotherapeutic drugs,i rinotecan (Iri)a nd paclitaxol (Tax), also elicited similar morphological changes during the drug loading process,e xcept that longer ultrasonication was needed in their cases to form the spherical structures ( Figure S7 ), which may be due to different physiochemical properties of these hydrophobic drugs.Ont he other hand, without hydrophobic drugs,t he nanofibers did not change their shape even after longer time of ultrasonication ( Figure S7 ), suggesting that hydrophobic drugs are necessary to the described morphological transformation. These observations are consistent with the proposed mechanism of the drug-induced reassembly process (Figure 1c) : ultrasonication increased the collision between hydrophobic drug molecules and nanofibers,during which the drug molecules inserted into the inner hydrophobic part of these fibers,f orming hydrophobic cores.T hese drugincorporated cores induced the rearrangement of surrounding peptide monomers through the hydrophobic driving force, resulting in the transformation into stable spherical NPs.
Taken together,these data indicate that we have successfully constructed an anocarrier for delivery of hydrophobic drugs using aF AP-a responsive peptide CAP.W ith proper size (sub-100 nm;T able S1), zeta potential (negative charges, Table S1 ), capacity of encapsulating hydrophobic drugs (Table S2) , as well as specific responsiveness to CAFs,t hese drug-peptide complexes hold great potential to be used for antitumor therapy.
Efficient and specific drug release is considered essential for ad rug delivery nanosystem to achieve high therapeutic efficacy. In our study,w ef ound that FAP-a was able to completely dissociate Dox-loaded CAPNPs (CAP-Dox) into disordered structures,but had no effect on the morphology of Dox-loaded UAPN Ps (UAP-Dox) (Figure 3a) . Without FAP-a,b oth CAP-Dox and UAP-Dox released Dox at similarly low rates (less than 40 %i n4 8h)( Figure S8 ). In contrast, CAP-Dox released almost all loaded drugs within 3h after FAP-a treatment, while UAP-Dox maintained the slow Dox release rate (Figure 3b ). This rapid drug release behavior of CAP-Dox in response to FAP-a was attributed to FAP-a triggered CAPc leavage,r esulting in two segments with unbalanced hydrophilicity and hydrophobicity (Figure S9 ). These structures are unable to maintain as table assembly or reassembly status.W ith rapid and efficient enzymatic response,o ur nanosystem is expected to greatly increase the effective drug concentration at the FAP-a-rich tumor sites,thus enhancing drug delivery/perfusion.
Most nanostructures with negative surface charge have been reported to suffer low cellular uptake. [21] To investigate the interaction between our drug-loading nanosystem and cells in vitro,wefirst incubated CAP-Dox or UAP-Dox with CAFs,P C-3 (a prostate cancer cell line) or human umbilical endothelial cells (HUVECs), and assessed the cellular uptake of encapsulated Dox ( Figure S10 ). Results showed that after CAP-Dox treatment for 4h,C AFs with high expression of FAP-a exhibited apronounced intracellular Dox signal while only asmall amount of Dox signal was observed in the FAPa negative cell lines,P C-3 and HUVEC ( Figure S11 ). Even after incubation for 24 h, the Dox signal was still very weak in PC-3 and HUVECs while most of the CAFs had been killed ( Figure S10 ). In comparison, all three types of cells only showed minimal Dox signal when treated with UAP-Dox, likely due to the lack of ac leavage site for FAP-a in UAP. These results are consistent with the difference between drug release profiles of the two NPs,suggesting that the high drug 
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Communications release efficiency of CAP-Dox would result in increased cellular uptake of drugs.I mportantly, when examined by cytotoxicity assays,C AP-Dox showed specific and dose-dependent cytotoxicity to CAFs and no significant toxicity to either PC-3 or HUVECs (Figure S12) , confirming the specificity of FAP-a responsive Dox release from CAP-Dox. As expected, UAP-Dox had no observable toxicity to any of the three cell types.Wenext used acoculture system (CAFs + PC-3 cells) to simulate atumor environment enriched with CAFs in vitro ( Figure S13 ). After CAP-Dox treatment for 4h,asignificant cellular uptake of Dox was observed in both cell types.Incontrast, little Dox uptake was detected in UAPDox treated cells.T hese results imply that other than selective drug release at CAF-present tumor sites to avoid off-target effects,t he specific response of CAP-Dox to FAP-a also allows the released Dox to act on not only CAFs but also the co-existing tumor cells.
Subsequently,w ea ssessed the tumor targeting and biodistribution of engineered nanocarrier in vivo.T etramethylrhodamine isothiocyanate (TRITC) and Black Hole Quencher (BHQ-1) were encapsulated in CAP, fabricating an anoprobe (CAP-RB,F igure S14), [22] which can be activated by FAP-a.T he in vivo imaging indicated that the tailor-made peptide nanocarrier specifically released its cargoes at the tumor site in the CAF-rich tumor model (Figure 4a ). Thebiodistribution results illustrated that CAPNPs possessed not only excellent tumor specificity but also low non-specific organ accumulation ( Figures S15, S16) .
Drug delivery efficiencyo ft he CAP nanocarriers to tumors was investigated by intravenous injection of free Dox, CAP-Dox and UAP-Dox (the same Dox dose,5mg kg À1 ,was used in all formulations) into mice bearing CAFs and PC-3 co-implants.A fter 24 hp ost-injection, tumors were resected and sectioned, and the tumor blood vessels were labeled with CD31 antibody.C onfocal microscopy images showed ag radient of Dox fluorescence from the tumor edge to the core that was much wider and stronger in CAP-Dox-treated tumors compared to either UAP-Dox or free Dox-treated groups (Figure 4b ,F igure S17). Although free Dox also exhibited ad egree of diffusion into tumors,i ts penetration distance was much shorter than that of CAP-Dox, as demonstrated by the fluorescence distribution across the tumor tissue.T his was probably caused by the low tumor targeting efficiencyo fD ox together with the drug expelling effect of high interstitial pressure.I nU AP-Dox treated tumors,f luorescence of Dox was detectable only at the tumor edge and with very low intensity,because of inefficient drug release and poor penetration through the stromal barrier.
Having confirmed the capacity of CAP-Dox to effectively release drugs and enhance drug delivery to tumors,wefurther examined its antitumor therapeutic efficacy.M ice were coinoculated with CAFs and PC-3 cells to establish axenograft prostate tumor model with enriched CAFs.W hen tumors reached an average volume of 100 mm 3 ,t he mice were randomly divided into five groups (n = 8) and intravenously injected with PBS (control), CAP,D ox, CAP-Dox, or UAP- 
Dox every three days (5 mg kg
À1 Dox per injection). Tumor volumes were measured and calculated post treatment (Figure 4c) . CAP-Dox significantly inhibited tumor growth after only two injections and gradually reduced tumor volume with subsequent treatment, exhibiting much superior antitumor effects to free Dox. In comparison, tumor growth in the UAPDox-treated group was only slightly suppressed. After four injections,tumor tissues were resected and subjected to H&E staining,i mmunohistochemistry (IHC) analysis of CAFs by labeling a-SMA, [23] and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining for apoptosis (Figure 4d and Figure S18 ). Compared to the control group, free Dox and UAP-Dox only showed am ild antitumor activity,b oth eliciting little change in tumor morphology, limited reduction of CAFs and no apparent apoptosis.I n contrast, the morphology of tumors in the CAP-Dox-treated group dramatically changed, with most cells in an apoptotic state.F urthermore,t he typical morphology of CAFs disappeared after CAP-Dox treatment ( Figure S18 and Figure 4d ). Thep ercentage of apoptotic cells determined in each group also supported the above observations ( Figure S18 ), as the TUNEL-positive cells in CAP-Dox treated tumors had ap ercentage about 65 AE 6.8 %, much higher than those in other groups (control, 7 AE 2%;D ox, 18 AE 3.4 %; UAP-Dox, 11 AE 2.5 %). These results suggest that the CAP-Dox nanosystem selectively and effectively respond to CAFs for drug release,and demonstrate promising antitumor efficacy.
Considering the cardiotoxicity of Dox and the distribution of CAP-NPs in liver and kidney for acertain period, [24] in vivo side effects of the peptide nanocarrier were evaluated (Figure S19) . Thec ontrol group showed as mall degree of morphological differences,w ith only the liver showing some apoptotic areas.However,noobvious morphological changes were observed in the UAP-Dox or CAP-Dox treated groups, indicating the minimal side effects of our designed peptide nanocarrier.
We further identified the versatility of the CAPn anosystem in another two xenograft tumor models,MCF-7 breast tumor and Mia-paca-2 pancreatic tumor. Although both tumor cell lines were FAP-a negative,they ultimately formed tumors that exhibited positive FAP-a expression (Figure S20) , indicating the presence of CAFs in the tumor microenvironment. When we used CAPnanoparticles loaded with Taxo rI ri to treat breast or pancreatic tumors, respectively,t umor growth was almost completely inhibited. Thea ntitumor efficiency of CAP-NPs was much higher than that of UAP-NPs or free drug ( Figure S21 ). These data further suggest that our CAP nanocarrier is of great potential for treatment of awide range of solid tumors that contain or recruit FAP-a positive CAFs.F urthermore,t he stability and responsive properties of CAP-NPs in blood ( Figure S22 ) imply the potential opportunity to apply CAP-NPs in clinical cancer therapy.
In summary,u sing the self-assembly properties of adesigned amphiphilic peptide,wedeveloped asmart Tr ansformers-like drug delivery system based on ac leavable amphiphilic peptide that specifically responded to FAPa expressed on CAFs in the tumor microenvironment, achieving enhanced drug delivery and promising antitumor effects.T he nanocarrier exhibited an interesting morphological transformation during the loading of hydrophobic drugs, and was able to rapidly disassemble upon cleavage by FAPa to release the drug, facilitating drug penetration into the tumor microenvironment. In vivo fluorescence imaging showed that the CAP nanocarrier possesses excellent tumor targeting specificity,w hich significantly reduced the side effects of the encapsulated chemotherapeutics on normal tissues.W ebelieve that our study demonstrated the potential utility of tumor microenvironment-responsive drug delivery nanosystems in enhancing both specific delivery and tumor penetration for antitumor therapy.
Experimental Section
All animal experiments were carried out in accordance with the national animal guidelines.Detailed experimentalprocedures for the synthesis and characterizations of CAP-NPs and UAP-NPs,m orphologiesfrom TEM and AFM, cell culture,tumor histology,toxicity evaluation,a nd therapeutic efficacyi nb reast and pancreatic tumor models are available in Supporting Information.
